BACKGROUND: Direct-Acting Antivirals (DAAs) are effective in 95% of patients, but concerns about potential cardiotoxicity and decreased Warfarin Sensitivity (WS) need further investigation. The study aimed to evaluate the safety and effectiveness of sofosbuvir-based therapy in patients with significant heart diseases, considering potential drug interactions and their impact on cardiac function. METHODS: The study involved 100 patients with HCV genotype 4, including 40 with ischemic heart disease, 20 with prosthetic valve replacement, 20 with NYHA class I‒II heart failure, and 20 with systemic hypertension. All received sofosbuvir-based antiviral therapy and underwent routine laboratory tests, N-Terminal B-type Natriuretic Peptide (NT-Pro BNP), abdominal ultrasound, and echocardiography at baseline and three months post-treatment. RESULTS: Ninety-six patients achieved SVR, resulting in improved cardiac ejection fraction (EF) from 53.2 ± 8.8% to 56.2 ± 6.9% (p = 0.000) and reduced left atrial volume (LAV) from 43.2 ± 4.2 to 41.7 ± 3.9 mm (p = 0.008). Liver stiffness also improved (p = 0.013), and no disabling symptoms were reported. MAPSE increased from 8.4 ± 2.4 mm to 9.5 ± 2.5 mm, and interventricular septum thickness (IVT) decreased from 12.5 ± 1.8 mm to 10.9 ± 1.3 mm (p = 0.001 and P = 0.000, respectively). The warfarin dose needed to be increased to optimize INR after SVR, but this adjustment did not affect WS (p = 0.16). CONCLUSION: Sofosbuvir-based antiviral therapy was well tolerated and demonstrated a reassuring cardiac safety profile in HCV patients with pre-existing heart disease, with no major arrhythmias or adverse cardiac events observed during or after therapy.
Hematological biomarkers have emerged as powerful tools in diagnosing Acute Heart Failure (AHF). This study introduces a novel diagnostic framework that integrates Explainable Artificial Intelligence (XAI) with Morris Sensitivity Analysis (MSA) to enhance both the interpretability and performance of machine learning models in AHF detection. A dataset consisting of 425 AHF patients and 430 controls was analyzed using eight machine learning models, including XGBoost, Histogram-based Gradient Boosting (histGB), Explainable Boosting Machine (EBM), and Random Forest. Model performance was evaluated through metrics such as AUC, accuracy, precision, recall, and Brier score. Hyperparameters were optimized via Bayesian optimization. Feature importance was assessed using MSA to identify variables with the highest predictive influence. The histGB model achieved the highest performance with an AUC of 87.93%. Both MSA and EBM consistently identified PDW, RDW-CV, NEU, NEU/LY ratio, age, and WBC as top predictive features across multiple models. These hematological markers demonstrated strong potential for early diagnosis and risk stratification in AHF patients. This study presents a clinically relevant, interpretable, and cost-effective diagnostic strategy that combines XAI with MSA for AHF prediction. The framework enhances clinical trust and provides a pathway toward personalized treatment by identifying accessible hematological biomarkers. The integration of explainability into AI models improves their transparency and applicability in real-world clinical settings.
Journal of the Saudi Heart Association · مجلد 35 (1) · 7-15
Background: The efficacy and safety of non-vitamin K-dependent anticoagulants (NOAC) are not well investigated in the obese population, and fixed dosing could lead to under-anticoagulation. Our objective was to evaluate the effect of obesity on anticoagulation outcomes and survival in non-valvular atrial fibrillation (AF) patients. Methods: We enrolled 755 patients who required anticoagulation for AF from 2015 to 2016. We grouped the patients into four groups. Group 1 (n = 297) included patients with BMI< 40 kg/m2 treated with NOACs, Group 2 (n = 358) included patients on warfarin with BMI< 40 kg/m2, Group 3 (n = 57) had patients on NOACs with BMI≥ 40 kg/m2 and Group 4 (n = 43) included patients on warfarin and BMI≥ 40 kg/m2. Study outcomes were the composite endpoint of stroke, bleeding, and survival. Results: Competing risk regression showed that stroke and bleeding were not affected by obesity or treatment (SHR: 1.09 (95% CI: 0.79-1.51); P = 0.62). Older age was the predictor of stroke/bleeding (HR:1.03 (95% CI:1.01-1.06); P = 0.02). Predictors of mortality were heart failure (HR:2.23 (95% CI:1.25-3.97); P = 0.007), lower creatinine clearance (HR: 0.98 (95% CI:0.97-0.98): P < 0.001), non-obese patients on warfarin (HR:3.51 (95%CI:1.6-7.7): P = 0.002) and obese patients on warfarin (HR: 6.7 (95% CI:2.51-17.92); P < 0.001). Conclusion: NOACs could have a similar risk profile to warfarin in obese and non-obese patients with non-valvular AF but could have better survival. Larger randomized trials are recommended.
International Journal of Community Medicine and Public Health · مجلد 10 (1) · 418-418
Bradyarrhythmias, which include physiological and pathological disorders such as sinus node dysfunction and atrioventricular conduction disturbances are frequent clinical findings in the emergency department. Although some benign bradyarrhythmias do not need treatment, acute unstable bradycardia can lead to cardiac arrest. A thorough history and physical examination should cover potential causes of sinoatrial node dysfunction or atrioventricular block in patients with confirmed or suspected bradycardia. Based on the severity of the symptoms, the underlying causes, the presence of possibly reversible causes, the presence of negative indications, and the danger of asystole progression, bradyarrhythmias are managed. Bradyarrhythmias that are unstable or symptomatic are treated with medication and/or pacing. Bradycardia is described as an adult heart rate of less than 60 beats per minute. Syncope, presyncope, momentary light-headedness or dizziness, exhaustion, dyspnea with exertion, heart failure symptoms, or disorientation brought on by cerebral hypoperfusion are typical signs of bradycardia. Atropine plays a significant role in the management of bradyarrhythmias because it counteracts the impact of the parasympathetic vagus nerve system, which can cause an increase in heart rate. Atropine administration is indicated in cases with vagus-mediated asystole, obstructions in the atrioventricular node, and sinus bradycardia. Installation of temporary pacemaker, permanent pacemaker is also among the effective management strategies of the bradyarrythmias. Diagnosis and management of bradyarrythmias in emergency department is of utmost importance since it can prevent morbidity and mortality. The purpose of this research is to review the available information about an overview of bradydysrhythmias in the emergency department.
Abstract Background Coronary artery bypass surgery is recommended for patients with extensive coronary artery disease and severely impaired left ventricular ejection fraction (LVEF). Short term clinical outcomes improved due to advanced surgical techniques and perioperative management. Objective To study the impact of pre-operative left ventricular ejection fraction (LV EF) on clinical outcomes during postoperative hospitalization and for 5 years follow up. Methods The study was a retrospective analysis of patients underwent CABG at our tertiary care hospital between January 2016 and August 2020.The primary outcome was mortality and the secondary outcomes included acute cerebrovascular stroke, length of hospitalization, subsequent revascularization, and heart failure. Results The study included 410 patients with a median age of 60 (55–68) years, a hospital mortality of 2.7%, postoperative stroke of 7.6%, acute kidney injury (AKI) of 25.6% and new need dialysis of 5.9%. The patients were divided into 4 groups: 75 (18.3%) patients had LV EF less than 35%, 88 (21.5%) had LV EF 35–45%, 106 (25.9%) had LV EF 45–55% and 141 (34.4%) had LV EF more than 55% with significant differences in frequencies of chronic kidney disease (29.3% vs. 40.9% vs. 23.6% vs. 24.1%, p=0.026), prior cerebral stroke (9.3% vs. 11.4% vs. 8.5% vs. 1.4%, p=0.015), Peripheral vascular disease (8% vs. 18.2% vs. 4.7% vs. 12.1%, p=0.019) respectively. The hospital mortality occurred in (6.7% vs. 0% vs. 0.9% vs. 3.5%, p=0.03), acute cerebrovascular stroke occurred in (14.7% vs. 6.8% vs. 3.8% vs. 7.1%, p=0.031), AKI occurred in (36% vs. 43.2% vs. 17.9% vs. 14.9%, p<0.001), new dialysis was used in (12% vs. 5.7% vs. 1.9% vs. 5.7%, p=0.04), ICU stay was [5 (3–7) vs. 4 (3–11) vs. 4 (3–5) vs. 3 (2–5), p<0.001], post ICU stay was [6 (3–10) vs. 5 (4–8) vs. 4 (3–6) vs. 4 (3–6), p=0.009] in patients with LV EF <35%, LV EF 35–45%, LV EF 45–55% and LV EF >55% respectively. Mortality during follow up occurred in (20% vs. 4.5% vs. 2.8% vs.4.3%, p<0.001), stroke occurred in (8% vs. 4.5% vs.0.9 5% vs. 2.8%, p=0.031), revascularization was done in (2.7% vs. 23.9% vs. 18.9% vs. 12.8%, p=0.009) and readmission with heart failure occurred in (52% vs. 34.1% vs. 10.4% vs. 4.3%, p<0.001) in patients with LV EF <35%, LV EF 35–45%, LV EF 45–55% and LV EF >55% respectively. Conclusion Reduced LV EF was associated with increased hospital mortality, frequent morbidities, and prolonged hospitalization after CABG with higher composite rate of death, stroke, heart failure at 5 years compared with normal or mildly reduced LV EF. Funding Acknowledgement Type of funding sources: None.
left ventricular ejection fractioncoronary artery bypass graftingpreoperative cardiac functionpostoperative mortality
International Journal of Community Medicine and Public Health · مجلد 9 (9) · 3613-3613
Shock is a clinical syndrome that results from lack of oxygen utilization or supply to vital organs resulting in hypoxia. Shock is associated with significant morbidity and mortality as if not treated timely can lead to multiple organ failure and death. The mortality rate of shock ranges from 20% to 50%. Shock has several pathophysiologies including intracardiac etiologies such as myocardial infarction, myopathy, or severe arrhythmia which produce altered maturation and cause heart failure while loss of internal or external fluid due to trauma or bleeding often results in hypovolemia. Also, obstruction by extracardiac causes and activation of inflammatory cascade can induce shock. The purpose of this research is to review the available information about the classification, pathophysiology and principle of therapy of shock. The major classification of shock includes cardiogenic, hypovolemic, obstructive and distributive shock. Distributive shock is further divided into three subclasses of septic, anaphylactic and neurogenic shock. Haemorrhagic shock is also the sub-type of hypovolemic shock. Each class of shock requires a specific treatment and timely management to prevent any further complications. Constant examination, resuscitation and re-evaluation are important in therapy of shock. To treat hypotension and to increase cardiac output, vasopressor drugs and inotropic adrenergic drugs continue to be the most widely used therapies. Endogenous catecholamines such as epinephrine, norepinephrine, and dopamine among other vasopressors have been shown to be effective in treating various types of shocks that are controlled as part of treatment for shock. Early diagnosis and prompt treatment can help in prevention of complications of shock also enhancing the recovery of patients.
International Journal of Morphology · مجلد 40 (5) · 1300-1307
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a unique class of glucose-declining renal-targeted drugs.The SGLT2i Canagliflozin (CANA) is an anti-hyperglycemic drug that reduces various cardiovascular and renal outcomes in patients with type 2 diabetes mellitus.This study aimed to explore the potential effects of CANA on the isolated healthy adult rat hearts to show if CANA has positive inotropic or cardiac depressant effects via analyzing the amplitude and frequency of cardiac contractions.In isolated normal adult rat hearts, the effects of CANA on cardiac contractility were examined.In a dose-response curve, CANA led to a significant cardiac depressant effect in a dose-dependent manner.This cardiac depressant effect of CANA (10 -6 M) was not prevented by atropine.However, this cardiac depressant effect was partially antagonized by both Isoproterenol (10 -5 M) and Calcium chloride (10 -6 M), suggesting beta-adrenoceptor and calcium channel blocking actions.In addition, the cardiac depressant effect of CANA (10 -6 M) was mitigated in part by Nitric oxide synthase inhibitor, L-NAME, suggesting that its action probably depends to some extent on the accumulation of nitric oxide, which decreases the rise of intracellular Calcium.Data from this study demonstrate that CANA has a significant cardiac relaxant effect in isolated hearts of healthy adult rats by different possible mechanisms.This inhibitory effect on cardiac contractility may help improve the diastolic ventricular filling providing a therapeutic potential to help the other cardioprotective mechanisms of CANA in the prevention and treatment of heart failure.
Saudi Journal of Biological Sciences · مجلد 29 (3) · 1306-1312
BACKGROUND AND OBJECTIVE: Coronavirus Disease 2019 (COVID-19) has affected millions of individuals all over the world. In addition to the patients' compelling indications, various sociodemographic characteristics were identified to influence infection complications. The purpose of this study was to assess the impact of the aforementioned parameters on the dissemination of COVID-19 among residents of Saudi Arabia's Riyadh region. MATERIALS AND METHODS: In the Saudi Arabian province of Riyadh, a cross-sectional retrospective analysis of COVID-19 incidences, recoveries, and case-fatality ratio (CFR) was undertaken. The study was carried out by gathering daily COVID-19 records from the ministry of health's official websites between October 2020 and September 2021. The influencing factors were obtained from the statistical authority. Using the SPSS IBM 25 software, the data was examined. The association between demographic factors as well as the presence of comorbidity on the COVID-19 outcome was determined using Spearman's correlation and regression tests. P < 0.05 was considered to indicate the significance of the results. RESULTS: The data from the study indicated that the highest number of COVID-19 cases were recorded in June 2021, and peak recovery was observed in July 2021. The CFR declined progressively from October 2020 to just over 1, even when the cases peaked. A significant (p < 0.05) correlation between diabetes and COVID-19 incidences was observed. The recovery rate had a significant (p < 0.05) association with the literacy rate and those aged 14-49 years old. Presences of co-morbidities such as Dyslipidemia, hypertension, diabetes, asthma, stroke and heart failure have negatively affected the recovery from COVID-19 in the population. The CFR is significantly (p < 0.05) associated with people over 60, hypertensive patients, and asthma patients. Regression analysis suggested that the risk of complications due to COVID-19 infection is more in males, people above 60 years age and those suffering from co-morbidities. CONCLUSIONS: The findings of the study indicate an association between several of the characteristics studied, such as gender, age, and comorbidity, and the spread of infection, recovery, and mortality. To restrict the spread of COVID-19 and prevent its complications, effective measures are required to control the modifiable risk factors.